Nuclear Imaging in Drug Discovery, Development, and Approval

  • Editors
  • H. Donald Burns
  • Raymond E. Gibson
  • Robert F. Dannals
  • Peter K. S. Siegl

Table of contents

  1. Front Matter
    Pages i-x
  2. Alfred P. Wolf, David J. Schlyer
    Pages 33-54
  3. Robert F. Dannals, Hayden T. Ravert, Alan A. Wilson
    Pages 55-74
  4. H. Donald Burns, Kwamena E. Baidoo, Alan A. Wilson
    Pages 75-112
  5. William C. Eckelman, Raymond E. Gibson
    Pages 113-134
  6. Raymond E. Gibson, Holly T. Beauchamp, Susan Iversen, Barry Everitt, James McCulloch, Christopher Wallace
    Pages 135-148
  7. Edwaldo E. Camargo, Zsolt Szabo, Robert F. Dannals, Henry N. Wagner Jr.
    Pages 167-177
  8. Joanna S. Fowler, Nora D. Volkow, Alfred P. Wolf
    Pages 179-200
  9. Linda W. Schaffer, John T. Davidson, Peter K. S. Siegl
    Pages 265-282
  10. Raymond E. Gibson, H. Donald Burns, William C. Eckelman
    Pages 321-331
  11. Back Matter
    Pages 333-344

About this book


It is the purpose and business of the pharmaceutical industry to dis­ cover, develop, and make available drugs for the care of the sick. The purpose of universities and national laboratories is to provide people and scientific knowledge that can help in the process. This book presents the combined efforts of scientists from the drug in­ dustry, academic laboratories and national laboratories to describe advances in radiotracer technology in studies on experimental ani­ mals and living human beings. The authors believe that the technol­ ogy is now ready for widespread application in the pharmaceutical industry. The goal of this book is to help bring this about. The field of Nuclear Medicine is based on the concept that, if treatment of disease is chemical, the patient's diagnosis should be chemical. Anatomy and histopathology have been the principle ba­ sis for making a diagnosis. Histopathologic data suffer from being descriptive, subjective, not quantifiable, and based on the study of dead tissue. The era of histopathology as the dominant concept in medical practice is coming to an end. Histopathologic findings are often heterogeneous and a single biopsy will at times not reveal the true nature of the disease, such as the grading of malignancy. Far greater accuracy of staging of disease and in the planning of treat­ ment is possible through chemistry, as well as by making possible a more suitable selection of a histological biopsy site.


anatomy chemistry drug discovery drug research drugs evaluation experiment medicine nature pharmaceutical pharmaceutical industry research research & development (R&D) technology tracer

Bibliographic information